10-Q
Quarterly Report
AGENUS INC
AGEN
NASDAQ
CIK: 1098972
File #: 000-29089
Balance Sheet
59 line items · 2 periods
XBRL
| Item | Jun 30, 2026 | Dec 31, 2025 |
|---|---|---|
ASSETS | ||
Cash and cash equivalents | 18,738,000 | 2,998,000 |
Estimated Fair Value | 436,000 | 417,000 |
Cost | 436,000 | 417,000 |
Institutional Money Market Funds - Cost | 436,000 | 417,000 |
Institutional Money Market Funds - Estimated Fair Value | 436,000 | 417,000 |
Zydus agreements escrow receivable (Note R) | 7,616,000 | 0 |
Zydus agreements contract assets (Note R) | 32,860,000 | 0 |
Zydus Agreements | 40,000,000 | — |
Accounts receivable | 14,725,000 | 1,831,000 |
Prepaid expenses | 2,853,000 | 785,000 |
Related Parties | 0 | 5,179,000 |
Assets held for sale | 0 | 121,554,000 |
Other current assets | 2,018,000 | 1,089,000 |
Total current assets | 78,810,000 | 133,436,000 |
MiNK Therapeutics, Inc. | 9,297,000 | — |
Property, plant and equipment, net of accumulated amortization and depreciation of $47,977 and $47,468 at June 30, 2026 and December 31, 2025, respectively | 14,322,000 | 15,470,000 |
Operating lease right-of-use assets | 7,205,000 | 7,744,000 |
Goodwill | 24,092,000 | 24,092,000 |
Acquired intangible assets, net of accumulated amortization of $17,482 and $17,325 at June 30, 2026 and December 31, 2025, respectively | 2,880,000 | 3,037,000 |
Equity method investment in MiNK Therapeutics, Inc. | 25,452,000 | 24,277,000 |
Related Parties | 16,075,000 | 15,435,000 |
MiNK Therapeutics, Inc. | 16,100,000 | — |
Other long-term assets | 3,856,000 | 3,307,000 |
Total assets | 172,692,000 | 226,798,000 |
LIABILITIES AND STOCKHOLDERS' DEFICIT | ||
Short-term debt | 30,068,000 | 44,655,000 |
Promissory Note | 24,635,000 | 24,052,000 |
2015 Subordinated Notes | 4,918,000 | 10,353,000 |
Debentures | 146,000 | 146,000 |
Other services | 369,000 | 104,000 |
Zydus Promissory Note | — | 10,000,000 |
Current portion, liability related to sale of future royalties and milestones (Note H) | 113,671,000 | 109,323,000 |
Current portion, operating lease liabilities | 1,102,000 | 1,034,000 |
Accounts payable | 58,984,000 | 82,987,000 |
Accrued liabilities | 27,515,000 | 34,223,000 |
Liabilities held for sale | 0 | 50,738,000 |
Other current liabilities | 480,000 | 529,000 |
Total current liabilities | 231,820,000 | 323,489,000 |
MiNK Therapeutics, Inc. | 7,569,000 | — |
Liability related to sale of future royalties and milestones, net of current portion (Note H) | 135,794,000 | 169,660,000 |
Deferred revenue | 1,143,000 | 1,143,000 |
Operating lease liabilities, net of current portion | 9,538,000 | 10,108,000 |
Other long-term liabilities | 247,000 | 259,000 |
STOCKHOLDERS" DEFICIT | ||
Series A-1 convertible preferred stock | 0 | 0 |
Common stock, par value $0.01 per share; 800,000,000 shares authorized; 42,615,618 and 35,320,397 shares issued and outstanding at June 30, 2026 and December 31, 2025, respectively | 427,000 | 353,000 |
Additional paid-in capital | 1,945,037,000 | 1,911,740,000 |
Accumulated other comprehensive loss | (450,000) | (439,000) |
Accumulated deficit | (2,144,089,000) | (2,182,765,000) |
Total stockholders' deficit attributable to Agenus Inc. | (199,075,000) | (271,111,000) |
Non-controlling interest | (6,775,000) | (6,750,000) |
Total stockholders' deficit | (205,850,000) | (277,861,000) |
Additional Paid-in Capital | 1,945,037,000 | 1,911,740,000 |
Common Stock | 427,000 | 353,000 |
Accumulated Deficit | (2,144,089,000) | (2,182,765,000) |
Accumulated Other Comprehensive Income (Loss) | (450,000) | (439,000) |
Non-controlling Interest | (6,775,000) | (6,750,000) |
Total liabilities and stockholders' deficit | 172,692,000 | 226,798,000 |